Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Petasites, commonly known as butterbur, is a botanical extract derived from the roots or leaves of the *Petasites hybridus* plant. It is primarily utilized for the preventive treatment of migraine and the management of allergic rhinitis. The active constituents, petasin and isopetasin, are believed to exert therapeutic effects through the inhibition of leukotriene synthesis (via 5-lipoxygenase inhibition) and by acting as L-type calcium channel blockers, which provide anti-inflammatory and antispasmodic properties. Clinical studies, including randomized controlled trials, have demonstrated that standardized, pyrrolizidine alkaloid-free extracts (such as Petadolex) significantly reduce the frequency of migraine attacks. Due to the presence of hepatotoxic and carcinogenic pyrrolizidine alkaloids in the raw plant, commercial preparations must be processed to remove these compounds to ensure safety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on petasites.